BTIG Downgrades Organogenesis Holdings (ORGO) to Neutral Amid Slower Recovery in Advanced Wound Care
BTIG downgraded its rating on Organogenesis Holdings Inc. (NASDAQ:ORGO) from Buy to Neutral following a Q1 update, citing slower-than-expected recovery in the company's Advanced Wound Care segment and market headwinds affecting demand trends and utilization levels.
Tickers: $ORGO
Topics: FDA submission pharmaceuticals regenerative medicine wound care